Full Text Journal Articles by
Author Brian M Shuch

Advertisement

Find full text journal articles








Role of Imaging in Renal Cell Carcinoma: A Multidisciplinary Perspective.

Asser M Abou Elkassem, Simon S Lo, Andrew J Gunn, Brian M Shuch, Molly E Dewitt-Foy, Robert Abouassaly, Sandeep S Vaidya, Joseph I Clark, Alexander V Louie, Shankar Siva, Anca-Ligia Grosu, Andrew D Smith,

With the expansion in cross-sectional imaging over the past few decades, there has been an increase in the number of incidentally detected renal masses and an increase in the incidence of renal cell carcinomas (RCCs). The complete characterization of an indeterminate renal mass on CT or MR images is challenging, ... Read more >>

Radiographics (Radiographics : a review publication of the Radiological Society of North America, Inc)
[2021, :200202]

Cited: 0 times

View full text PDF listing >>



68Ga-FAPI-46 and 18F-FDG PET/CT in a patient with immune-related thyroiditis induced by immune checkpoint inhibitors.

Masatoshi Hotta, Ida Sonni, Matthias R Benz, Andrei Gafita, Shadfar Bahri, Brian M Shuch, Run Yu, Sandy Ting Liu, Johannes Czernin, Jeremie Calais,

Eur J Nucl Med Mol Imaging (European journal of nuclear medicine and molecular imaging)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Novel Liquid Biomarkers and Innovative Imaging for Kidney Cancer Diagnosis: What Can Be Implemented in Our Practice Today? A Systematic Review of the Literature.

Riccardo Campi, Grant D Stewart, Michael Staehler, Saeed Dabestani, Markus A Kuczyk, Brian M Shuch, Antonio Finelli, Axel Bex, Börje Ljungberg, Umberto Capitanio,

<h4>Context</h4>The epidemiological signature of renal cell carcinoma (RCC) during the past decades is explained by overdetection and overtreatment of indolent cancers; furthermore, a non-negligible proportion of patients undergoing surgery for suspected RCC harbour benign renal tumours. As the gold standard for RCC diagnosis remains histopathological analysis of surgical or biopsy ... Read more >>

Eur Urol Oncol (European urology oncology)
[2021, 4(1):22-41]

Cited: 0 times

View full text PDF listing >>



Reply by Authors.

Daniel M Geynisman, Brian T Kadow, Brian M Shuch, Stephen A Boorjian, Surena F Matin, Edward Rampersaud, Barton N Milestone, Elizabeth R Plimack, Matthew R Zibelman, Alexander Kutikov, Marc C Smaldone, David Yt Chen, Rosalia Viterbo, Shreyas Joshi, Richard E Greenberg, Lois Malizzia, Thomas McGowan, Eric A Ross, Robert G Uzzo,

J Urol (The Journal of urology)
[2020, 204(3):536-537]

Cited: 0 times

View full text PDF listing >>



Analysis of guideline recommended use of renal mass biopsy and association with treatment.

Joaquin Michel, Andrew T Lenis, Patrick M Lec, Vishnukamal Golla, David C Johnson, Kiran Gollapudi, Jeremy Blumberg, Brian M Shuch, Karim Chamie,

<h4>Introduction</h4>Renal mass biopsy (RMB) may not be indicated when the results are unlikely to impact management, such as in young and/or healthy patients and in elderly and/or frail patients. We analyzed the utility of RMB in three patient cohorts stratified by age-adjusted Charlson comorbidity index score (ACCI).<h4>Materials and methods</h4>We identified ... Read more >>

Can J Urol (The Canadian journal of urology)
[2020, 27(4):10285-10293]

Cited: 0 times

View full text PDF listing >>



Oncometabolites suppress DNA repair by disrupting local chromatin signalling.

Parker L Sulkowski, Sebastian Oeck, Jonathan Dow, Nicholas G Economos, Lily Mirfakhraie, Yanfeng Liu, Katelyn Noronha, Xun Bao, Jing Li, Brian M Shuch, Megan C King, Ranjit S Bindra, Peter M Glazer,

Deregulation of metabolism and disruption of genome integrity are hallmarks of cancer<sup>1</sup>. Increased levels of the metabolites 2-hydroxyglutarate, succinate and fumarate occur in human malignancies owing to somatic mutations in the isocitrate dehydrogenase-1 or -2 (IDH1 or IDH2) genes, or germline mutations in the fumarate hydratase (FH) and succinate dehydrogenase ... Read more >>

Nature (Nature)
[2020, 582(7813):586-591]

Cited: 23 times

View full text PDF listing >>



Sporadic Angiomyolipomas Growth Kinetics While on Everolimus: Results of a Phase II Trial.

Daniel M Geynisman, Brian T Kadow, Brian M Shuch, Stephen A Boorjian, Surena F Matin, Edward Rampersaud, Barton N Milestone, Elizabeth R Plimack, Matthew R Zibelman, Alexander Kutikov, Marc C Smaldone, David Yt Chen, Rosalia Viterbo, Shreyas Joshi, Richard E Greenberg, Lois Malizzia, Thomas McGowan, Eric A Ross, Robert G Uzzo,

PURPOSE:Everolimus decreases tumor volume of renal angiomyolipomas in patients with tuberous sclerosis. No prospective data are available regarding the effect of everolimus on the growth kinetics in patients with sporadic angiomyolipomas. We sought to determine the safety and efficacy of everolimus in the volumetric reduction of sporadic angiomyolipomas. MATERIALS AND ... Read more >>

J Urol (The Journal of urology)
[2020, 204(3):531-537]

Cited: 0 times

View full text PDF listing >>



Development of a 2-dimensional atlas of the human kidney with imaging mass cytometry.

Nikhil Singh, Zachary M Avigan, Judith A Kliegel, Brian M Shuch, Ruth R Montgomery, Gilbert W Moeckel, Lloyd G Cantley,

An incomplete understanding of the biology of the human kidney, including the relative abundances of and interactions between intrinsic and immune cells, has long constrained the development of therapies for kidney disease. The small amount of tissue obtained by renal biopsy has previously limited the ability to use patient samples ... Read more >>

JCI Insight (JCI insight)
[2019, 4(12):]

Cited: 2 times

View full text PDF listing >>



Inhibition of Heat Shock Protein 90 suppresses TWIST1 Transcription.

Kay Yi Chong, Min Kang, Francesca Garofalo, Daiki Ueno, Huamao Liang, Sarah Cady, Oluwagbemisola Madarikan, Nicholas Pitruzzello, Cheng-Hsiu Tsai, Tobias M P Hartwich, Brian M Shuch, Yang Yang-Hartwich,

Molecular chaperone heat shock protein 90 (HSP90) is involved in oncogenic signaling pathways including epithelial-mesenchymal transition (EMT), a key process in tumor initiation, progression, metastasis, and chemoresistance. The molecular mechanisms underlying the involvement of HSP90 in EMT are still under investigation. In this study, we identified a previously unrecognized role ... Read more >>

Mol Pharmacol (Molecular pharmacology)
[2019, 96(2):168-179]

Cited: 5 times

View full text PDF listing >>



The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?

Hiten D Patel, Maneka Puligandla, Brian M Shuch, Bradley C Leibovich, Anil Kapoor, Viraj A Master, Charles G Drake, Daniel Yc Heng, Primo N Lara, Toni K Choueiri, Deborah Maskens, Eric A Singer, Scott E Eggener, Robert S Svatek, Walter M Stadler, Suzanne Cole, Sabina Signoretti, Rajan T Gupta, Marc Dror Michaelson, David F McDermott, David Cella, Lynne I Wagner, Naomi B Haas, Michael A Carducci, Lauren C Harshman, Mohamad E Allaf,

Patients with high-risk renal cell carcinoma (RCC) experience high rates of recurrence despite definitive surgical resection. Recent trials of adjuvant tyrosine kinase inhibitor therapy have provided conflicting efficacy results at the cost of significant adverse events. PD-1 blockade via monoclonal antibodies has emerged as an effective disease-modifying treatment for metastatic ... Read more >>

Future Oncol (Future oncology (London, England))
[2019, 15(15):1683-1695]

Cited: 4 times

View full text PDF listing >>



Inherited kidney cancer syndromes.

Mark W Ball, Brian M Shuch,

<h4>Purpose of review</h4>To describe current paradigms for genetic testing, screening, and treatment of patients with inherited kidney cancer syndromes.<h4>Recent findings</h4>We describe various new aspects of hereditary kidney cancer. Recent data now support that hereditary kidney cancer may account for 5-8% of kidney cancers diagnosed. Methods of testing have evolved including ... Read more >>

Curr Opin Urol (Current opinion in urology)
[2019, 29(4):334-343]

Cited: 4 times

View full text PDF listing >>



Considerations for the Next Clinical Trial Evaluating the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma.

Hyung L Kim, Eddie Mayerson, Primo N Lara, Edward Messing, Cathy Tangen, Brian M Shuch, Ulka Vaishampayan,

Trials SWOG 8949 and EORTC 30947 had the same eligibility criteria and established the role of cytoreductive nephrectomy for metastatic renal cell carcinoma. The more recently published CARMENA trial calls into question the need for cytoreductive nephrectomy. A systematic comparison of CARMENA and SWOG 8949 suggests that cytoreductive nephrectomy may ... Read more >>

Eur Urol Focus (European urology focus)
[2019, 5(6):927-929]

Cited: 4 times

View full text PDF listing >>



Whole-genome analysis of papillary kidney cancer finds significant noncoding alterations.

Shantao Li, Brian M Shuch, Mark B Gerstein,

To date, studies on papillary renal-cell carcinoma (pRCC) have largely focused on coding alterations in traditional drivers, particularly the tyrosine-kinase, Met. However, for a significant fraction of tumors, researchers have been unable to determine a clear molecular etiology. To address this, we perform the first whole-genome analysis of pRCC. Elaborating ... Read more >>

PLoS Genet (PLoS genetics)
[2017, 13(3):e1006685]

Cited: 20 times

View full text PDF listing >>



The association between chronic renal failure and renal cell carcinoma may differ between black and white Americans.

Jonathan N Hofmann, Kendra Schwartz, Wong-Ho Chow, Julie J Ruterbusch, Brian M Shuch, Sara Karami, Nathaniel Rothman, Sholom Wacholder, Barry I Graubard, Joanne S Colt, Mark P Purdue,

<h4>Purpose</h4>In the United States, renal cell carcinoma (RCC) incidence is higher among blacks than among whites. Risk of RCC is elevated among end-stage renal disease patients, although no studies have looked at differences by race in the relationship between chronic renal failure and RCC.<h4>Methods</h4>We investigated RCC risk in relation to ... Read more >>

Cancer Causes Control (Cancer causes & control : CCC)
[2013, 24(1):167-174]

Cited: 21 times

View full text PDF listing >>



Prognostic factors in renal cell carcinoma.

Brian M Shuch, John S Lam, Arie S Belldegrun, Robert A Figlin,

The identification of prognostic factors in patients with renal cell carcinoma (RCC) represents an area of increasing interest. The tumor, node, metastasis (TNM) staging system is currently the most extensively used tool for providing prognostic information for RCC. Data published in the last few years have led to significant controversies ... Read more >>

Semin Oncol (Seminars in oncology)
[2006, 33(5):563-575]

Cited: 18 times

View full text PDF listing >>





Advertisement

Disclaimer
0.9014 s